Inovio Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
529900B9W875XDZXTM97 - ISIN
US45773H4092 (INO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Read full profile
Stock price
Fundamentals
- Net revenue
€713.87K - Gross margin
100.0% - EBIT
-€123.50M - EBIT margin
-17,300.3% - Net income
-€115.93M - Net margin
-16,239.9%
Statement period: - (published )
Dividends
- Last dividend amount
-
$0.01 - Ex date
-
- Payment date
-
Earnings Calls
Latest earnings call: May 13, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |